Psoriasis Clinical Trials in Philadelphia
View 22 new treatments for Psoriasis in Philadelphia, PA near me. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.Secukinumab for Nail Psoriasis
Research Clinic, Philadelphia + 1 more
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.Show More
No Placebo Trial
COVID-19 VaccinE Response in Rheumatology Patients
Research Clinic, Philadelphia + 1 more
This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
No Placebo Trial
Deucravacitinib for Palmoplantar Pustulosis
Research Clinic, Philadelphia + 1 more
This trial tests a pill called deucravacitinib in adults with severe PPP who haven't responded to other treatments. The medication aims to reduce inflammation and calm the immune system, improving symptoms like redness and swelling. Deucravacitinib has shown efficacy in treating moderate to severe plaque psoriasis.Show More
No Placebo Trial
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Wyomissing + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
No Placebo Trial
ESK-001 for Psoriasis
Alumis Clinic, Philadelphia + 1 more
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Wyomissing + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Wyomissing + 1 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Philadelphia + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Philadelphia + 1 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Exton + 2 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
No Placebo Trial
Frequently Asked Questions
How much do psoriasis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do psoriasis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Philadelphia, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Philadelphia is research being conducted for psoriasis?
Prominent hospitals in Philadelphia conducting psoriasis clinical trials include the University of Pennsylvania and the Hospital at the University of Pennsylvania. Approximately 7 trials are ongoing in the western part of the city as of 2024.
What promising new drugs are being tested?
In Philadelphia, psoriasis research is focusing on treatments like Monoclonal Antibodies and Janus kinase (JAK) inhibitors. Notable drugs being studied include Guselkumab, JNJ-77242113, and Deucravacitinib.